Home All Products GLP 1 Cagrilintide | SMA
GLP 1 Cagrilintide | SMA
GLP 1 Cagrilintide | SMA

GLP 1 Cagrilintide | SMA

CagriSMA is a fixed-dose, co-formulated therapy combining Cagrilintide (2.4 mg), a long-acting amylin analog, with SMA (2.4 mg), a GLP-1 receptor agonist. Delivered as a single once-weekly subcutaneous injection, CagriSema leverages complementary pathways for appetite regulation, glycemic control, and metabolic optimization.

  • Cagrilintide – an amylin and calcitonin receptor agonist with a half-life of ~184 hours, enhancing satiety, delaying gastric emptying, and suppressing postprandial glucagon through brainstem signaling.

  • SMA – a GLP-1 receptor agonist with a half-life of ~158 hours, driving glucose-dependent insulin secretion, further glucagon suppression, and hypothalamic appetite regulation.

The combination provides dual appetite suppression and superior metabolic outcomes, with clinical efficacy approaching that of bariatric surgery. For research use only. Not for human or veterinary consumption. Not intended for diagnostic or therapeutic applications

  1. Garvey WT, et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity. N Engl J Med. Published online June 22, 2025. doi:10.1056/NEJMoa2502081
  2. Davies MJ, et al. Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes. N Engl J Med. Published online June 22, 2025. doi:10.1056/NEJMoa2502082
  3. Frias JP, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2023;402(10401):529-544. doi:10.1016/S0140-6736(23)01163-7
  4. Dutta D, et al. Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (CagriSema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis. Indian J Endocrinol Metab. 2024;28(5):436-444. doi:10.4103/ijem.ijem_45_24
  5. Enebo LB, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021;397(10257):1736-1748. doi:10.1016/S0140-6736(21)00845-X
  • Weight Loss Superiority: Up to 22.7% mean bodyweight reduction at 68 weeks.
  • High Responder Rate: ~60% of patients achieved ≥20% weight loss.
  • Glycemic Control: Mean HbA1c reduction of 2.07%; 74% achieved HbA1c ≤6.5%.
  • Dual Appetite Suppression: Targeting both homeostatic and hedonic eating pathways.
  • Cardiovascular Benefits: Reductions in systolic blood pressure and improvements in lipid profile.
  • Diabetes Remission Potential: Durable improvements in weight and glycemic indices.
  • Favorable Tolerability: Mostly GI-related adverse events with relatively low discontinuation.
  • Flexible Dosing: Clinically meaningful weight loss achieved even below maximum dosing levels.

$150.00

Per Unit
In stock

Free Shipping on All Orders $1000+